Lipids & metabolic liver disease
Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes
Main finding · Receipt of EBMResult — go to the resultAdjusted odds ratio 0.75 95% CI 0.59–0.96Authors' conclusion
Racial disparities exist in the receipt of EBM among patients with T2D and presumptive MASLD. These findings highlight the need for research to identify drivers of disparities, and to support development of clinical interventions that equitably facilitate EBM of MASLD in patients with T2D.
Study context
- Population
- Patients with T2D and presumptive MASLD (≥1 alanine aminotransferase ≥30 U/L, excluding alcohol overuse, viral hepatitis, liver transplantation, chemotherapy, other liver disease), academic health care system, 2019–2021; mean age 58.0 (SD 13.1), 41.7% female
- Participants
- 6,532 patients
- Exposure
- Non-Latino (NL) Black vs NL White patients
- Outcome
- Receipt of EBM: composite of liver US, transient elastography or hepatology evaluation
Methodological detailssingle academic health care system
- Single academic health care system
Main finding
Receipt of EBM
Adjusted odds ratio
0.75
95% CI 0.59–0.96
NL Blackvs NL White
aOR 0.75 (95% CI 0.59–0.96)
As reported in the abstract
- Rates of evidence-based management (EBM) low overall
- 11.5%
Observational data: associations, not effects.
Further findings
Hepatology evaluation and placement of MASLD diagnosis codes
- Odds of hepatology evaluation and MASLD diagnosis codes lower in NL Black vs NL White patients
Original publication
Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes. Endocr Pract. Published 1 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →